Cargando…

Integrated proteogenomic characterization of urothelial carcinoma of the bladder

BACKGROUND: Urothelial carcinoma (UC) is the most common pathological type of bladder cancer, a malignant tumor. However, an integrated multi-omics analysis of the Chinese UC patient cohort is lacking. METHODS: We performed an integrated multi-omics analysis, including whole-exome sequencing, RNA-se...

Descripción completa

Detalles Bibliográficos
Autores principales: Xu, Ning, Yao, Zhenmei, Shang, Guoguo, Ye, Dingwei, Wang, Haixing, Zhang, Hailiang, Qu, Yuanyuan, Xu, Fujiang, Wang, Yunzhi, Qin, Zhaoyu, Zhu, Jiajun, Zhang, Fan, Feng, Jinwen, Tian, Sha, Liu, Yang, Zhao, Jianyuan, Hou, Jun, Guo, Jianming, Hou, Yingyong, Ding, Chen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9164575/
https://www.ncbi.nlm.nih.gov/pubmed/35659036
http://dx.doi.org/10.1186/s13045-022-01291-7
_version_ 1784720165460508672
author Xu, Ning
Yao, Zhenmei
Shang, Guoguo
Ye, Dingwei
Wang, Haixing
Zhang, Hailiang
Qu, Yuanyuan
Xu, Fujiang
Wang, Yunzhi
Qin, Zhaoyu
Zhu, Jiajun
Zhang, Fan
Feng, Jinwen
Tian, Sha
Liu, Yang
Zhao, Jianyuan
Hou, Jun
Guo, Jianming
Hou, Yingyong
Ding, Chen
author_facet Xu, Ning
Yao, Zhenmei
Shang, Guoguo
Ye, Dingwei
Wang, Haixing
Zhang, Hailiang
Qu, Yuanyuan
Xu, Fujiang
Wang, Yunzhi
Qin, Zhaoyu
Zhu, Jiajun
Zhang, Fan
Feng, Jinwen
Tian, Sha
Liu, Yang
Zhao, Jianyuan
Hou, Jun
Guo, Jianming
Hou, Yingyong
Ding, Chen
author_sort Xu, Ning
collection PubMed
description BACKGROUND: Urothelial carcinoma (UC) is the most common pathological type of bladder cancer, a malignant tumor. However, an integrated multi-omics analysis of the Chinese UC patient cohort is lacking. METHODS: We performed an integrated multi-omics analysis, including whole-exome sequencing, RNA-seq, proteomic, and phosphoproteomic analysis of 116 Chinese UC patients, comprising 45 non-muscle-invasive bladder cancer patients (NMIBCs) and 71 muscle-invasive bladder cancer patients (MIBCs). RESULT: Proteogenomic integration analysis indicated that SND1 and CDK5 amplifications on chromosome 7q were associated with the activation of STAT3, which was relevant to tumor proliferation. Chromosome 5p gain in NMIBC patients was a high-risk factor, through modulating actin cytoskeleton implicating in tumor cells invasion. Phosphoproteomic analysis of tumors and morphologically normal human urothelium produced UC-associated activated kinases, including CDK1 and PRKDC. Proteomic analysis identified three groups, U-I, U-II, and U-III, reflecting distinct clinical prognosis and molecular signatures. Immune subtypes of UC tumors revealed a complex immune landscape and suggested the amplification of TRAF2 related to the increased expression of PD-L1. Additionally, increased GARS, related to subtype U-II, was validated to promote pentose phosphate pathway by inhibiting activities of PGK1 and PKM2. CONCLUSIONS: This study provides a valuable resource for researchers and clinicians to further identify molecular pathogenesis and therapeutic opportunities in urothelial carcinoma of the bladder. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13045-022-01291-7.
format Online
Article
Text
id pubmed-9164575
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-91645752022-06-04 Integrated proteogenomic characterization of urothelial carcinoma of the bladder Xu, Ning Yao, Zhenmei Shang, Guoguo Ye, Dingwei Wang, Haixing Zhang, Hailiang Qu, Yuanyuan Xu, Fujiang Wang, Yunzhi Qin, Zhaoyu Zhu, Jiajun Zhang, Fan Feng, Jinwen Tian, Sha Liu, Yang Zhao, Jianyuan Hou, Jun Guo, Jianming Hou, Yingyong Ding, Chen J Hematol Oncol Research BACKGROUND: Urothelial carcinoma (UC) is the most common pathological type of bladder cancer, a malignant tumor. However, an integrated multi-omics analysis of the Chinese UC patient cohort is lacking. METHODS: We performed an integrated multi-omics analysis, including whole-exome sequencing, RNA-seq, proteomic, and phosphoproteomic analysis of 116 Chinese UC patients, comprising 45 non-muscle-invasive bladder cancer patients (NMIBCs) and 71 muscle-invasive bladder cancer patients (MIBCs). RESULT: Proteogenomic integration analysis indicated that SND1 and CDK5 amplifications on chromosome 7q were associated with the activation of STAT3, which was relevant to tumor proliferation. Chromosome 5p gain in NMIBC patients was a high-risk factor, through modulating actin cytoskeleton implicating in tumor cells invasion. Phosphoproteomic analysis of tumors and morphologically normal human urothelium produced UC-associated activated kinases, including CDK1 and PRKDC. Proteomic analysis identified three groups, U-I, U-II, and U-III, reflecting distinct clinical prognosis and molecular signatures. Immune subtypes of UC tumors revealed a complex immune landscape and suggested the amplification of TRAF2 related to the increased expression of PD-L1. Additionally, increased GARS, related to subtype U-II, was validated to promote pentose phosphate pathway by inhibiting activities of PGK1 and PKM2. CONCLUSIONS: This study provides a valuable resource for researchers and clinicians to further identify molecular pathogenesis and therapeutic opportunities in urothelial carcinoma of the bladder. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13045-022-01291-7. BioMed Central 2022-06-03 /pmc/articles/PMC9164575/ /pubmed/35659036 http://dx.doi.org/10.1186/s13045-022-01291-7 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Xu, Ning
Yao, Zhenmei
Shang, Guoguo
Ye, Dingwei
Wang, Haixing
Zhang, Hailiang
Qu, Yuanyuan
Xu, Fujiang
Wang, Yunzhi
Qin, Zhaoyu
Zhu, Jiajun
Zhang, Fan
Feng, Jinwen
Tian, Sha
Liu, Yang
Zhao, Jianyuan
Hou, Jun
Guo, Jianming
Hou, Yingyong
Ding, Chen
Integrated proteogenomic characterization of urothelial carcinoma of the bladder
title Integrated proteogenomic characterization of urothelial carcinoma of the bladder
title_full Integrated proteogenomic characterization of urothelial carcinoma of the bladder
title_fullStr Integrated proteogenomic characterization of urothelial carcinoma of the bladder
title_full_unstemmed Integrated proteogenomic characterization of urothelial carcinoma of the bladder
title_short Integrated proteogenomic characterization of urothelial carcinoma of the bladder
title_sort integrated proteogenomic characterization of urothelial carcinoma of the bladder
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9164575/
https://www.ncbi.nlm.nih.gov/pubmed/35659036
http://dx.doi.org/10.1186/s13045-022-01291-7
work_keys_str_mv AT xuning integratedproteogenomiccharacterizationofurothelialcarcinomaofthebladder
AT yaozhenmei integratedproteogenomiccharacterizationofurothelialcarcinomaofthebladder
AT shangguoguo integratedproteogenomiccharacterizationofurothelialcarcinomaofthebladder
AT yedingwei integratedproteogenomiccharacterizationofurothelialcarcinomaofthebladder
AT wanghaixing integratedproteogenomiccharacterizationofurothelialcarcinomaofthebladder
AT zhanghailiang integratedproteogenomiccharacterizationofurothelialcarcinomaofthebladder
AT quyuanyuan integratedproteogenomiccharacterizationofurothelialcarcinomaofthebladder
AT xufujiang integratedproteogenomiccharacterizationofurothelialcarcinomaofthebladder
AT wangyunzhi integratedproteogenomiccharacterizationofurothelialcarcinomaofthebladder
AT qinzhaoyu integratedproteogenomiccharacterizationofurothelialcarcinomaofthebladder
AT zhujiajun integratedproteogenomiccharacterizationofurothelialcarcinomaofthebladder
AT zhangfan integratedproteogenomiccharacterizationofurothelialcarcinomaofthebladder
AT fengjinwen integratedproteogenomiccharacterizationofurothelialcarcinomaofthebladder
AT tiansha integratedproteogenomiccharacterizationofurothelialcarcinomaofthebladder
AT liuyang integratedproteogenomiccharacterizationofurothelialcarcinomaofthebladder
AT zhaojianyuan integratedproteogenomiccharacterizationofurothelialcarcinomaofthebladder
AT houjun integratedproteogenomiccharacterizationofurothelialcarcinomaofthebladder
AT guojianming integratedproteogenomiccharacterizationofurothelialcarcinomaofthebladder
AT houyingyong integratedproteogenomiccharacterizationofurothelialcarcinomaofthebladder
AT dingchen integratedproteogenomiccharacterizationofurothelialcarcinomaofthebladder